Proteins binding NKG2D, CD16 and a tumor-associated antigen

Patent metadata

Field	Value
Publication number	US-12378318-B2
Application number	US-201917266966-A
Country	US
Kind code	B2
Filing date	Aug 8, 2019
Priority date	Aug 8, 2018
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

Multi-specific binding proteins that bind NKG2D receptor, CD 16, and a tumor-associated antigen selected from c-MET, KIT, F3, IGF1R, Lewis Y, MUC13, MUC4, MCAM, LRRC32, sialyl-Tn, gpA33, GD3, GM2, EPHA3, TNFRSF10A, TNFSF11, CD74, and PMEL are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

First claim

What is claimed is:

1. A trispecific binding protein comprising an Fc region that binds CD16 and two antigen binding sites, wherein the two antigen binding sites consist of a first antigen binding site that binds NKG2D and a second antigen binding site that binds cMET, wherein the protein comprises three polypeptides, and wherein
a) the first polypeptide comprises, from N-terminus to C-terminus,
i) a heavy chain variable domain of a Fab fragment that binds NKG2D,
ii) a CH1 domain,
iii) a first CH2 domain and
iv) a first CH3 domain;

b) the second polypeptide comprises, from N-terminus to C-terminus,
i) a light chain variable domain of the Fab fragment that binds NKG2D and
ii) a CL domain;

c) the third polypeptide comprises, from N-terminus to C-terminus,
i) an scFv that binds cMET,
ii) a second CH2 domain and
iii) a second CH3 domain,
(1) wherein the heavy chain variable domain of the Fab fragment that binds NKG2D comprises CDR1, CDR2, and CDR3 of amino acid sequence SEQ ID NO: 387, SEQ ID NO: 88, and SEQ ID NO: 390, respectively; and the light chain variable domain of the Fab fragment that binds NKG2D comprises CDR1, CDR2, and CDR3 of amino acid sequence SEQ ID NO: 90, SEQ ID NO: 91, and SEQ ID NO: 92, respectively; and
(2) wherein a heavy chain variable domain of the scFv that binds cMET comprises CDR1, CDR2, and CDR3 of amino acid sequence SEQ ID NO: 414, SEQ ID NO: 415, and SEQ ID NO: 416, respectively; and a light chain variable domain of the scFv that binds cMET comprises CDR1, CDR2, and CDR3 of amino acid sequence SEQ ID NO: 418, SEQ ID NO: 419, and SEQ ID NO: 420, respectively; and
(3) wherein the Fc region comprises the first CH2 domain, first CH3 domain, second CH2 domain and second CH3 domain.

2. The protein according to claim 1 , wherein the first antigen-binding site that binds NKG2D comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 388 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 86.

3. The protein according to claim 2 , wherein the second antigen-binding site that binds cMET comprises an scFv heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 413 and an scFv light chain variable domain comprising the amino acid sequence of SEQ ID NO: 417.

4. The protein according to claim 3 , wherein the scFv heavy chain variable domain forms a disulfide bridge with the scFv light chain variable domain.

5. The protein according to claim 2 , wherein the second antigen-binding site that binds cMET comprises an scFv heavy chain variable domain comprising the amino acid sequence SEQ ID NO: 413 with a G44C mutation using the Kabat numbering system and an scFv light chain variable domain comprising the amino acid sequence of SEQ ID NO: 417 with a G100C mutation using the Kabat numbering system, wherein the scFv heavy chain variable domain forms a disulfide bridge with the scFv light chain variable domain between the cysteine at position 44 from the scFv heavy chain variable domain and the cysteine at position 100 from the scFv light chain variable domain.

6. The protein according to claim 5 , wherein the scFv heavy chain variable domain is linked to the scFv light chain variable domain via a flexible linker.

7. The protein according to claim 6 , wherein the flexible linker comprises (G4S)4.

8. The protein according to claim 7 , wherein the scFv heavy chain variable domain is positioned at the C-terminus of the scFv light chain variable domain within the scFv.

9. The protein according to claim 3 , wherein the Fc region comprises an amino acid sequence of the Fc region of human IgG1, wherein one chain of the Fc region comprises S354C, Q347R, D399V, and F405T mutations, and the other chain of the Fc region comprises Y349C, K360E, and K409W mutations, according to the EU index as in Kabat.

10. The protein according to claim 8 , wherein the Fc region comprises an amino acid sequence of the Fc region of human IgG1, wherein one chain of the Fc region comprises S354C, Q347R, D399V, and F405T mutations, and the other chain of the Fc region comprises Y349C, K360E, and K409W mutations, according to the EU index as in Kabat.

11. A trispecific binding protein comprising an Fc region that binds CD16 and two antigen binding sites, wherein the two antigen binding sites consist of a first antigen binding site that binds NKG2D and a second antigen binding site that binds cMET, wherein the protein comprises three polypeptides, and wherein
a) the first polypeptide comprises, from N-terminus to C-terminus,
i) a heavy chain variable domain of a Fab fragment that binds NKG2D,
ii) an IgG1 CH1 domain,
iii) a first IgG1 CH2 domain and
iv) a first IgG1 CH3 domain;

b) the second polypeptide comprises, from N-terminus to C-terminus,
i) a light chain variable domain of the Fab fragment that binds NKG2D and
ii) a CL domain;

c) the third polypeptide comprises, from N-terminus to C-terminus,
i) an scFv that binds cMET,
ii) a second IgG1 CH2 domain and
iii) a second IgG1 CH3 domain,
(1) wherein the heavy chain variable domain of the Fab fragment that binds NKG2D comprises amino acid sequence SEQ ID NO: 388 and the light chain variable domain of the Fab fragment that binds NKG2D comprises the amino acid sequence SEQ ID NO: 86;
(2) wherein a heavy chain variable domain of the scFv that binds cMET comprises the amino acid sequence of SEQ ID NO: 413 with a G44C mutation using the Kabat numbering system; and a light chain variable domain of the scFv that binds cMET comprises the amino acid sequence SEQ ID NO: 417 with a G100C mutation using the Kabat numbering system, wherein the heavy chain variable domain of the scFv that binds cMET is linked to the light chain variable domain of the scFv that binds cMET via a (G4S) 4 linker, wherein the scFv heavy chain variable domain is positioned at the C-terminus of the scFv light chain variable domain within the scFv, and wherein the scFv heavy chain variable domain forms a disulfide bridge with the scFv light chain variable domain between the cysteine at position 44 from the scFv heavy chain variable domain and the cysteine at position 100 from the scFv light chain variable domain; and
(3) wherein the Fc region comprises two amino acid chains, wherein the first amino acid chain comprises the first IgG1 CH2 domain and the first IgG1 CH3 domain, and the second amino acid chain comprises the second IgG1 CH2 domain and the second IgG1 CH3 domain, wherein one chain of the Fc region comprises S354C, Q347R, D399V, and F405T mutations, and the other chain of the Fc region comprises Y349C, K360E, and K409W mutations, according to the EU index as in Kabat.

Assignees

• Dragonfly Therapeutics Inc

Inventors

• Chang Gregory P
• Cheung Ann F
• Du Jinyan
• Fallon Daniel
• Grinberg Asya
• Haney William
• Lunde Bradley M
• O'Neil Steven
• Prinz Bianka
• Wei Ronnie

Classifications

• C07K2317/55

  Fab or Fab' · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title